SCHEMBL6797556

SCHEMBL6797556

CCC(CC)Nc1cc(C)nc(Oc2ccc(Br)cc2OC)c1C(N)=O

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 1/20 0.40
GAA P10253 3/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.37
PKM P14618 1/20 0.37
MGAM O43451 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
RXFP1 Q9HBX9 1/20 0.36
SIK1 P57059 1/20 0.35
SIK2 Q9H0K1 1/20 0.35
SIK3 Q9Y2K2 1/20 0.35
POLB P06746 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6798584 0.91 MGAM (0.42) CRHR1GAAHPGDMAPTKDM4E
SCHEMBL6793891 0.89 CRHR1 (0.40) CRHR1GAAHPGDMAPTKDM4E
SCHEMBL6798867 0.88 GAA (0.50) CRHR1GAAHPGDHSD17B10MAPT
SCHEMBL6798157 0.81 CRHR1 (0.57) CRHR1
SCHEMBL6796943 0.80 CRHR1 (0.42) CRHR1GAAHPGDHSD17B10KDM4E
SCHEMBL6792226 0.79 RXFP1 (0.41) CRHR1GAAHPGDMAPTRXFP1
SCHEMBL6796886 0.79 GAA (0.41) CRHR1GAAHPGDMAPT
SCHEMBL6797700 0.78 CRHR1 (0.56) CRHR1
SCHEMBL6798731 0.77 SLC6A2 (0.45) CRHR1GAAHPGDHSD17B10POLB
SCHEMBL6796427 0.77 GAA (0.41) CRHR1GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6833378-B2 Pyridines, pyrimidines, purinones, pyrrolopyrimidinones and pyrrolopyridinones; useful in the treatment disorders including CNS and stress-related disorders. PFIZER INC 2004-12-21 US claimed
US-20020016328-A1 Corticotropin releasing factor antagonists PFIZER INC. 2002-02-07 US claimed
US-6833378-B2 Pyridines, pyrimidines, purinones, pyrrolopyrimidinones and pyrrolopyridinones; useful in the treatment disorders including CNS and stress-related disorders. PFIZER INC 2004-12-21 US disclosed
EP-1263732-A1 CORTICOTROPIN RELEASING FACTOR ANTAGONISTS Pfizer Products Inc. (US) 2002-12-11 EP disclosed
US-20020016328-A1 Corticotropin releasing factor antagonists PFIZER INC. 2002-02-07 US disclosed
WO-2001053263-A1 CORTICOTROPIN RELEASING FACTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2001-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020016328-A1 Corticotropin releasing factor antagonists CRH, CRHR2, CRHR1 CRHR1 3/4885GAA 2029/4885HPGD 3224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.